^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
FS222
i
Other names: FS222, FS-222, FS 222
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
PD-L1 inhibitor, CD137 agonist
Related drugs:
over1year
FS222, A Tetravalent Bispecific CD137 and PD-L1 Targeting Antibody, Modulates Anti-Tumor Immunity Preclinically and Demonstrates Pharmacology in Patients in an Ongoing Phase I Trial (EACR 2023)
Based on preclinical PK/PD, selected PD and biomarker endpoints have been incorporated into the FIH study design.ConclusionFS222 mechanism of action, as described in preclinical studies, appeared to translate to the emerging clinical pharmacology profile observed in patients in the Phase I study. Use of bioinformatics analysis pipelines enabled efficient handling of clinical pharmacology data.
P1 data • Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFRSF9 (TNF Receptor Superfamily Member 9) • FCGR2A (Fc fragment of IgG receptor IIa)
|
FS222
2years
First-in-human study to evaluate the safety and clinical activity of FS222, a tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors (ESMO-IO 2022)
The CR remained persistent 10 months later. Conclusions Thus far, FS222 has demonstrated manageable tolerability and early signs of antitumor activity.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
PD-L1 underexpression • PD-L1-L
|
FS222
3years
A First-in-Human Phase 1 Study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies. (ESMO-IO 2021)
Legal entity responsible for the study F-star Therapeutics. Funding F-star Therapeutics.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
FS222
over4years
FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models. (PubMed, Clin Cancer Res)
By targeting CD137 agonism to areas of PD-L1 expression, predominantly found in the tumour microenvironment, FS222 has the potential to leverage a focused, potent and safe immune response augmenting the PD-(L)1 axis blockade.
Preclinical • Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
FS222
Share via
